ACH-126443. Anti-HBV, anti-HIV

Drugs of the Future

Volumn 27, Issue 12, 2002, Pages 1131-1140

  Sorbera, L A ^a   Castaner J ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE; 2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)GUANINE; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; ALPHA INTERFERON; ALUMINUM MAGNESIUM HYDROXIDE; AMDOXOVIR; AMPRENAVIR; ANTIVIRUS AGENT; BAY 41 4109; BETA 2',3' DIDEHYDRO 2',3' DIDEOXY 5 FLUOROCYTIDINE; CLEVUDINE; DIDANOSINE; DW 977; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; MIV 210; NELFINAVIR; NUCLEOSIDE ANALOG; REMOFOVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TELBIVUDINE; TORCITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALTORCITABINE; ZALCITABINE; ZIDOVUDINE;

CANCER CELL CULTURE; CELL MUTANT; CHRONIC DISEASE; CLINICAL TRIAL; CYTOTOXICITY; DISEASE ASSOCIATION; DNA REPLICATION; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIVER INJURY; MORTALITY; NONHUMAN; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION;

EID: 0037001153     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.12.713266     Document Type: Review

References (26)

1. Chen, S.-H., Xiuyan, L. (Vion Pharmaceuticals, Inc.). Processes for high-yield diastereoselective synthesis of dideoxynucleosides. WO 9747635.
2. Chen, S.-H., Li, X., Li, J., Niu, C., Carmichael, E., Doyle, T.W. Stereoselective syntheses of β-L-FD4C and β-L-FddC. J Org Chem 1997, 62: 3449-52.
3. Holy, A. Nucleic acid components and their analogues. CLIII. Preparation of 2′-deoxy-L-ribonucleosides of the pyrimidine series. Coll Czech Chem Commun 1972, 37: 4072-86.
4. Lin, T.-S., Luo, M-.Z., Liu, M.-C., Zhu, Y.-L., Gullen, E., Dutschman, G.E., Cheng, Y.-C. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J Med Chem 1996, 39: 1757-9.
5. Lin, T.-S., Cheng, Y.-C. (Yale University). L-2′,3′-Dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents. EP 0707481, JP 1996510747, US 5627160, WO 9427616.
6. Schinazi, R.F., Liotta, D.C. (Emory University). [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides. EP 0805683, JP 1998512887, US 5703058, WO 9622778.
7. Prous Science Drug R&D Backgrounders: Hepatitis B (online publication). Updated December 15, 2002.
8. Shaw, T., Locarnini, S. Combination chemotherapy for hepatitis B virus: The path forward? Drugs 2000, 60: 517-31.
9. Shaw, T., Locarnini, S.A. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepat 1999, 6: 89-106.
10. Shaw, T., Locarnini, S.A. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis. Liver 1995, 15: 169-84.
11. Chen, S.-H., Lin, S., King, I., Spinka, T., Dutschman, G.E., Gullen, E.A., Cheng, Y.-C., Doyle, T.W. Synthesis and comparative evaluation of two antiviral agents: β-L-Fd4C and β-D-Fd4C. Bioorg Med Chem Lett 1998, 8: 3245-50.
12. Zhu, Y.-L., Dutschman, D.E., Liu, S.-H., Bridges, E.G., Cheng, Y.-C. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L-(-)- 5-fluorocytidine. Antimicrob Agents Chemother 1998, 42: 1805-10.
13. Dutschman, G.E., Bridges, E.G., Liu, S.-H., Gullen, E., Guo, X., Kukhanova, M., Cheng, Y.-C. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L-(-)- 5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D-(+) nucleoside analogs in vitro. Antimicrob Agents Chemother 1998, 42: 1799-804.
14. Fu, L., Liu, S.-H., Cheng, Y.-C. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999, 57: 1351-9.
15. Fu, L., Cheng, Y.-C. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother 2000, 44: 3402-7.
16. Dunkle, L.M., Oshana, S.C., Cheng, Y.-C., Hertogs, K., Rice, W.G. ACH-126,443: A new nucleoside analog with potent activity against wild-type and resistant HIV-1 and a promising pharmacokinetic and mitochondrial safety profile. 8th Conf Retroviruses Opportunistic Infect (Feb 4-8, CHicago) 2001, Abst 303.
17. Schinazi, R.F., Schlueter-Wirtz, S., Stuyver, L. Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. Antivir Chem Chemother 2001, 12(Suppl. 1): 61-5.
18. Le Guerhier, F., Pichoud, C., Guerret, S. et al. Characterization of the antiviral effect of 2′,3′-dideoxy-2′,3′-didehydro-β-L-5- fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000, 44: 111-22.
19. Le Guerhier, F., Pichoud, C., Jamard, C. et al. Antiviral activity of β-L-2′,3′-dideoxy-2′,3′-didehydro-5- fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother 2001, 45: 1065-77.
20. Cheng Y.-C. L-Nucleoside analogues against cancer-causing viruses have potential in the prevention, delayed onset and treatment of viral associated cancers. Antivir Chem Chemother 2001, 12(Suppl. 1): 5-11.
21. Cheng, Y.-C. Potential use of antiviral L-(-)nucleoside analogues for the prevention or treatment of viral associated cancers. Cancer Lett 2001, 162(Suppl.): S33-7.
22. Dunkle, L.M., Oshana, S.C., Rice, W.G. Potency and pharmacokinetics of ACH-126,443 suggest utility for treatment of lamivudine-resistant hepatitis B infection. Hepatology 2001, 34(4, Part 2): Abst 1814.
23. Dunkle, L.M., Oshana, S., Dickson, J., Cheng, Y., Rice, W.G. Phase 1 safety and pharmacokinetics of ACH-126,443, a potent anti-HIV and HBV nucleoside. 41st Intersci Conf Antimicrob Agents Chemother (Dec 16-19, Chicago) 2001, Abst A-508.
24. Afdhal, N., O'Brien, C., Oshana, S., Dunkle, L. Rapid, potent anti-HBV activity of ACH-126,443 in a phase 1/2 trial in chronic hepatitis B infection. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst V-690.
25. Afdhal, N.H., O'Brien, C.B., Oshana, S.C., Dunkle, L.M. Potent anti-HBV activity of ACH-126,443 correlated with 14-day pharmacokinetics and safety: Predictions for activity against YMDD mutant strains. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1-5, Boston) 2002, Abst 837.
26. β-L-Fd4C to treat HBV and HIV. Achillion Web Site November 4, 2002.